National trends of surgery for benign prostatic hyperplasia in Finland
DOI:
https://doi.org/10.2340/sju.v59.32425Keywords:
benign prostatic hyperplasia, national trends, transurethral resection of the prostate, photoselective vaporization of the prostate, incidenceAbstract
Purpose: To investigate national trends of surgical treatment for benign prostatic obstruction (BPO).
Methods: The Care Register for Healthcare in Finland was used to investigate the annual numbers and types of surgical procedures, operation incidence and duration of hospital stay between 2004 and 2018 in Finland. Procedures were classified using the Nordic Medico-Statistical Committee Classification of Surgical Procedures coding. Trends in incidence were analyzed with two-sided Cochran-Armitage test. Trends in duration of hospital stay and patient age were analyzed with linear regression.
Results: Transurethral resection of the prostate (TURP) was the most common operation type during the study period, covering over 70% of operations for BPO. Simultaneous with the implementation of photoselective vaporization of the prostate (PVP), the incidence of TURP, minimally invasive surgical therapies, transurethral vaporization of the prostate (TUVP) and open prostatectomies decreased (p < 0.05). The mean operation incidence rate in the population between 2004 and 2018 was 263 per 100,000. The duration of hospital stay shortened (p < 0.05), and the average age of operated patients increased by 2 years (p < 0.0001).
Conclusion: The implementation of PVP did not challenge the dominating position of TURP in Finland, but it has probably influenced the overall use of other surgical therapies, excluding transurethral incision of the prostate. The results might suggest that the conservative treatment is accentuated, patient selection is more thorough, and surgical intervention might be placed at a later stage of BPO.
Downloads
References
Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–140.
https://doi.org/10.1016/j.eururo.2013.03.004 DOI: https://doi.org/10.1016/j.eururo.2013.03.004
Cornu JN, Gacci HHM, Herrmann TRW, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. EAU Guidelines Office, Arnhem, the Netherlands; 2023.
Gilfrich C, Leicht H, Fahlenbrach C, et al. Morbidity and mortality after surgery for lower urinary tract symptoms: a study of 95 577 cases from a nationwide German health insurance database. Prostate Cancer Prostatic Dis. 2016;19:406–411.
https://doi.org/10.1038/pcan.2016.33 DOI: https://doi.org/10.1038/pcan.2016.33
Salmivalli A, Ettala O, Nurminen P, et al. Short- and long-term risks of photoselective laser vaporization of the prostate: a population-based comparison with transurethral resection of the prostate. Ann Med. 2023;55:1287–1294.
https://doi.org/10.1080/07853890.2023.2192046 DOI: https://doi.org/10.1080/07853890.2023.2192046
Salmivalli A, Ettala O, Boström PJ, et al. Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. World J Urol. 2022;40:1785–1791.
https://doi.org/10.1007/s00345-022-03999-0 DOI: https://doi.org/10.1007/s00345-022-03999-0
Hoffman RM, Monga M, Elliot SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2007; 4. DOI: https://doi.org/10.1002/14651858.CD004135.pub2
Bouza C, López T, Magro A, et al. Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006;6:1–17.
https://doi.org/10.1186/1471-2490-6-14 DOI: https://doi.org/10.1186/1471-2490-6-14
Christidis D, McGrath S, Perera M, et al. Minimally invasive surgical therapies for benign prostatic hypertrophy: the rise in minimally invasive surgical therapies. Prostate Int. 2017;5:41–46.
https://doi.org/10.1016/j.prnil.2017.01.007 DOI: https://doi.org/10.1016/j.prnil.2017.01.007
Brunken C, Seitz C, Woo HH. A systematic review of experience of 180-W XPS GreenLight laser vaporisation of the prostate in 1640 men. BJU Int. 2015;116:531–537.
https://doi.org/10.1111/bju.12955 DOI: https://doi.org/10.1111/bju.12955
Kauppila JH, Helminen O, Kytö V, et al. Short-term outcomes following minimally invasive and open esophagectomy: a population-based study from Finland and Sweden. Ann Surg Oncol. 2018;25:326–332.
https://doi.org/10.1245/s10434-017-6212-9 DOI: https://doi.org/10.1245/s10434-017-6212-9
Te AE, Malloy TR, Stein BS, et al. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int. 2006;97:1229–1233.
https://doi.org/10.1111/j.1464-410X.2006.06197.x DOI: https://doi.org/10.1111/j.1464-410X.2006.06197.x
Al-Ansari A, Younes N, Sampige VP, et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol. 2010;58:349–355.
https://doi.org/10.1016/j.eururo.2010.05.026 DOI: https://doi.org/10.1016/j.eururo.2010.05.026
Zang YC, Deng XX, Yang DR, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis of randomized controlled trials. Lasers Med Sci. 2016;31:235–240.
https://doi.org/10.1007/s10103-015-1843-1 DOI: https://doi.org/10.1007/s10103-015-1843-1
Bachmann A, Schürch L, Ruszat R, et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol. 2005;48:965–972.
https://doi.org/10.1016/j.eururo.2005.07.001 DOI: https://doi.org/10.1016/j.eururo.2005.07.001
Hermanns T, Gross O, Kranzbühler B, et al. Ablative efficiency of 532-nm laser vaporization compared to transurethral resection of the prostate: results from a prospective three-dimensional ultrasound volumetry study. World J Urol. 2014;32:1267–1274.
https://doi.org/10.1007/s00345-013-1203-3 DOI: https://doi.org/10.1007/s00345-013-1203-3
Teng J, Zhang D, Li Y, et al. Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta-analysis. BJU Int. 2013;111:312–323.
https://doi.org/10.1111/j.1464-410X.2012.11395.x DOI: https://doi.org/10.1111/j.1464-410X.2012.11395.x
Patel RM, Bariol S. National trends in surgical therapy for benign prostatic hyperplasia in Australia. ANZ J Surg. 2019;89:345–349.
https://doi.org/10.1111/ans.15016 DOI: https://doi.org/10.1111/ans.15016
Morton A, Williams M, Perera M, et al. Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. BJU Int. 2020;126:18–26.
https://doi.org/10.1111/bju.15098 DOI: https://doi.org/10.1111/bju.15098
Peyronnet B, Cornu J-N, Rouprët M, et al. Trends in the use of the green light laser in the surgical management of benign prostatic obstruction in France over the past 10 years. Eur Urol. 2015;67:1193–1197.
https://doi.org/10.1016/j.eururo.2015.01.003 DOI: https://doi.org/10.1016/j.eururo.2015.01.003
Schroeck FR, Hollingsworth JM, Kaufman SR, et al. Population based trends in the surgical treatment of benign prostatic hyperplasia. J Urol. 2012;188:1837–1841.
https://doi.org/10.1016/j.juro.2012.07.049 DOI: https://doi.org/10.1016/j.juro.2012.07.049
LaBossiere JR, Wallis CJD, Herschorn S, et al. Surgical management of benign prostatic obstruction: 20-year population-level trends. Can Urol Assoc J. 2020;14:552–557.
https://doi.org/10.5489/cuaj.6224 DOI: https://doi.org/10.5489/cuaj.6224
Malaeb BS, Yu X, McBean AM, et al. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000–2008). Urology. 2012;79:1111–1117.
https://doi.org/10.1016/j.urology.2011.11.084 DOI: https://doi.org/10.1016/j.urology.2011.11.084
Stenmark F, Brudin L, Kjölhede H, et al. Treatment with CoreTherm in 570 patients with prostate volumes of 80–366 ml: an evaluation of short- and long-term retreatment risk. Scand J Urol. 2022;56:336–341.
https://doi.org/10.1080/21681805.2022.2108139 DOI: https://doi.org/10.1080/21681805.2022.2108139
Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health. 2012;40:505–515.
https://doi.org/10.1177/1403494812456637 DOI: https://doi.org/10.1177/1403494812456637
Verhamme KMC, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinarytract symptoms suggestive of benign prostatic hyperplasia in Primary CareöTheTriumph Project. Eur Urol. 2002;42:323–328.
https://doi.org/10.1016/S0302-2838(02)00354-8 DOI: https://doi.org/10.1016/S0302-2838(02)00354-8
Lee YJ, Lee JW, Park J, et al. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol. 2016;57:424–430. DOI: https://doi.org/10.4111/icu.2016.57.6.424
Thangasamy IA, Chalasani V, Bachmann A, et al. Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol. 2012;62:315–323.
https://doi.org/10.1016/j.eururo.2012.04.051 DOI: https://doi.org/10.1016/j.eururo.2012.04.051
Treharne C, Crowe L, Booth D, et al. Economic value of the transurethral resection in saline system for treatment of benign prostatic hyperplasia in England and wales: systematic review, meta-analysis, and cost–consequence model. Eur Urol Focus. 2018;4:270–279.
https://doi.org/10.1016/j.euf.2016.03.002 DOI: https://doi.org/10.1016/j.euf.2016.03.002
Garden EB, Ravivarapu KT, Levy M, et al. The utilization and safety of same-day discharge after transurethral benign prostatic hyperplasia surgery: a case-control, matched analysis of a national cohort. Urology. 2022;165:59–66.
https://doi.org/10.1016/j.urology.2022.01.037 DOI: https://doi.org/10.1016/j.urology.2022.01.037
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alisa Salmivalli, Peter J. Boström, Pertti Nurminen, Pekka Kinnala, Ville Kytö, Otto Ettala
This work is licensed under a Creative Commons Attribution 4.0 International License.
Acta Chirurgica Scandinavica Society owns the copyright for all material published until Volume 57 (2023) unless otherwise specified. As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
